Proposed CMS Rule Reshapes Medicare Part D: Impact on PBMs
The Centers for Medicare & Medicaid Services (CMS) has released a proposed rule aimed at reshaping key aspects of Medicare Part D, with significant implications for pharmacy benefit managers (PBMs) and stakeholders across the insurance landscape.
Released on October 16, 2026, the proposed rule sets out to implement tenets of the Consolidated Appropriations Act of 2026, targeting implementation from January 1, 2028. Among its provisions, the rule proposes stringent guidelines on the remuneration practices of PBMs related to Part D drugs. These changes signal a shift towards increased transparency and accountability in pharmaceutical pricing and benefit management, potentially impacting how PBMs operate within the Medicare framework.
Key Changes in PBM Remuneration Practices
The proposed guidelines redefine the permissible scope of bona fide service fees (BFSFs) for PBMs. Specifically, the CMS mandates that BFSFs should only cover payments for services actually performed, at flat rates calibrated using a cost-plus method reflective of fair market value. The rule prohibits any linkage of these fees to drug prices, rebates, or the volume of business. This move is part of a broader initiative to decouple PBM compensation from incentivized drug pricing arrangements, seeking to align reimbursements more closely with verifiable services provided.
Moreover, CMS insists on complete pass-through of manufacturer rebates and concessions on Part D drugs to the plan sponsors, ensuring that the full economic value ultimately benefits the sponsor. This transition is poised to recalibrate financial dynamics, fostering greater fiscal responsibility and reducing potential conflicts of interest.
Enhanced Reporting and Compliance Measures
The proposed rule requires PBMs to furnish annual detailed reports to both CMS and plan sponsors. These reports will include information on covered drugs, cost-sharing frameworks, and comprehensive financial arrangements. Such transparency is designed to empower CMS and sponsors to verify that PBM compensation is in line with market value, facilitating the recovery of funds if discrepancies are detected. The emphasis on detailed disclosure marks a significant step towards mitigating non-compliance risks.
| Provision | Impact |
|---|---|
| Bona Fide Service Fees | Require fair market value assessments, removing link to drug prices. |
| Rebate Transparency | Ensures full pass-through to plan sponsors, altering financial flows. |
| Annual Reporting | Demands detailed financial disclosures to enhance compliance monitoring. |
Consumer Protections and Provider Directories
In addition to PBM-specific measures, the CMS proposes enhancements to Medicare Advantage (MA) plans' online provider directories. The aim is to increase accuracy, requiring quarterly verifications and swift updates following any changes. Starting in 2029, CMS plans to evaluate and publicly grade these directories' accuracy, which could influence consumer trust and plan selection.
Further consumer protections include the elimination of the $1 generic drug copayment for certain beneficiaries, transitioning to a $0 flat rate beginning in 2028. This change aims to remove financial barriers to accessing necessary medications, enhancing overall beneficiary support.
What Stakeholders Should Anticipate
Insurance professionals, including carriers, brokers, and claims managers, should prepare for a landscape characterized by heightened regulatory scrutiny and shifting operational norms. For agents and agencies, understanding the implications of these changes on client plans and benefits will be essential for providing informed guidance. Stakeholders may submit feedback on the proposed rule until December 15, 2026, allowing them to influence its finalization and implementation.